BrookeDawn NicoleEstevesDO

PubMed

• 7 citations
  A Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal Malignancies
  Corina N.A.M. Oldenhuis, Walter J. Loos, Brooke Esteves, Leni van Doorn, Monette M. Cotreau, Andrew Strahs, Martha W. den Hollander, Jourik A. Gietema, Elisabeth G.E. ...> ;Clinical Colorectal Cancer. 2015 Mar 1
• 310 citations
  Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
  Robert J. Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy, Oleg Lipatov, Piotr Tomczak, Oleksiy Lyulko, Anna Alyasova, Mihai Harza, Mikhail Koga...> ;Journal of Clinical Oncology. 2013 Oct 20
• 21 citations
  Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
  Mayer Fishman, Sandy Srinivas, Ralph J. Hauke, Robert J. Amato, Brooke Esteves, Monette M. Cotreau, Andrew Strahs, William Slichenmyer, P. Bhargava, Fairooz F. Kabbinavar> ;European Journal of Cancer. 2013 Sep 1
• 87 citations
  Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
  Dmitry Nosov, Brooke Esteves, Oleg Lipatov, Alexei A. Lyulko, A. A. Anischenko, Raju Titus Chacko, Dinesh C. Doval, Andrew Strahs, William Slichenmyer, Pankaj Bhargava> ;Journal of Clinical Oncology. 2012 May 10
• 76 citations
  Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedu...
  Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni va...> ;Clinical Cancer Research. 2011 Nov 15
• Join now to see all